Relevant bibliographies by topics / VMAT2 Inhibitor

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'VMAT2 Inhibitor'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'VMAT2 Inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "VMAT2 Inhibitor"

1

Meyer, Jonathan M., Craig Chepke, Rimal B. Bera, et al. "Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review." Mental Health Clinician 13, no. 5 (2023): 225–32. http://dx.doi.org/10.9740/mhc.2023.10.225.

Full text
Abstract:
Abstract Introduction Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was to elucidate clinician-reported improvement in symptoms and any noticeable changes in social or physical well-being in patients receiving VMAT2 inhibitors. Methods A web-based survey was offered to physicians, nurse practitioners, and physician assistants based in the US who prescribed valbe
APA, Harvard, Vancouver, ISO, and other styles
2

Yaffe, Dana, Ariela Vergara-Jaque, Lucy R. Forrest, and Shimon Schuldiner. "Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis." Proceedings of the National Academy of Sciences 113, no. 47 (2016): E7390—E7398. http://dx.doi.org/10.1073/pnas.1605162113.

Full text
Abstract:
Neurotransporters located in synaptic vesicles are essential for communication between nerve cells in a process mediated by neurotransmitters. Vesicular monoamine transporter (VMAT), a member of the largest superfamily of transporters, mediates transport of monoamines to synaptic vesicles and storage organelles in a process that involves exchange of two H+ per substrate. VMAT transport is inhibited by the competitive inhibitor reserpine, a second-line agent to treat hypertension, and by the noncompetitive inhibitor tetrabenazine, presently in use for symptomatic treatment of hyperkinetic disor
APA, Harvard, Vancouver, ISO, and other styles
3

Peckham, Alyssa M., and Jessica A. Nicewonder. "VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications." Journal of Pharmacy Practice 32, no. 4 (2018): 450–57. http://dx.doi.org/10.1177/0897190018756512.

Full text
Abstract:
Tardive dyskinesia is a potentially irreversible, debilitating, hyperkinetic movement disorder that can result from dopamine receptor antagonists. Prompt recognition and resolution of symptoms are instrumental in preventing disease irreversibility, though current treatment options have fallen short of robust, effective, and long-term symptom control. In April 2017, the Food and Drug Administration (FDA) approved 2 new vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine and valbenazine, for chorea related to Huntington’s disease and tardive dyskinesia, respectively. These age
APA, Harvard, Vancouver, ISO, and other styles
4

Kazumori, Hideaki, Shunji Ishihara, Mohammad A. K. Rumi, Cesar F. Ortega-Cava, Yasunori Kadowaki та Yoshikazu Kinoshita. "Transforming growth factor-α directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells". American Journal of Physiology-Gastrointestinal and Liver Physiology 286, № 3 (2004): G508—G514. http://dx.doi.org/10.1152/ajpgi.00269.2003.

Full text
Abstract:
For the production and vesicle storage of histamine, Enterochromaffin-like (ECL) cells express histidine decarboxylase (HDC) and vesicular monoamine transporter 2 (VMAT2). Although HDC and VMAT2 show dynamic changes during gastric ulcer healing, the control system of their expression has not been fully investigated. In the present study, we investigated the effect of transforming growth factor-α (TGF-α) and proinflammatory cytokines on HDC and VMAT2 expression in rat ECL cells. Time course changes in the expression of TGF-α during the healing of acetic acid-induced ulcers were studied. EGF rec
APA, Harvard, Vancouver, ISO, and other styles
5

Wiley, Shereta, Wendy Cerenzia, Sylvie Stacy, Chirag Shah, Leslie Lundt, and Khody Farahmand. "Understanding the Evolving Continuing Medical Education Needs of Physicians Managing Patients with TD." CNS Spectrums 26, no. 2 (2021): 149. http://dx.doi.org/10.1017/s1092852920002369.

Full text
Abstract:
AbstractThis study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD). A case-based survey was developed, and later updated, to assess current practice, knowledge, and attitudes of neurologists and psychiatrists in the management of patients with TD. The original and updated survey were fielded in May 2018 and March 2020, respectively, to US-practicing psychiatrists and neurologists. Results were obtained from 213 psychiatrists and 187 neurologists in 2018 and from 125 psychiatrists and 128 neurologists in 202
APA, Harvard, Vancouver, ISO, and other styles
6

Meyer, Jonathan M., Ericha Franey, Leslie Lundt, et al. "Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors." CNS Spectrums 26, no. 2 (2021): 151. http://dx.doi.org/10.1017/s1092852920002400.

Full text
Abstract:
AbstractObjectiveVesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with antipsychotic exposure. This real-world study was performed to assess the association between patient awareness of TD symptoms and clinician-assessed symptom severity.MethodsClinicians who treated antipsychotic-induced TD with a VMAT2 inhibitor within the past 24 months were asked to extract demographic/clinical data from patients charts and complete a survey for additional data, including patient awaren
APA, Harvard, Vancouver, ISO, and other styles
7

Kimura, Shunsuke, Masahiro Sekiguchi, Kentaro Watanabe, et al. "Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism." PLOS ONE 16, no. 1 (2021): e0245526. http://dx.doi.org/10.1371/journal.pone.0245526.

Full text
Abstract:
Neuroblastoma, the most common extracranial solid malignancy among children, originates from undifferentiated neural crest cells (NCC). Despite recent intensified treatment, high-risk patients still have a high mortality rate. To explore a new therapeutic strategy, we performed an integrated genomic and transcriptomic analysis of 30 high-risk neuroblastoma cases. Based on the expression profiling of RNA sequencing, neuroblastoma was classified into Mesenchymal (MES; n = 5) and Noradrenergic (ADRN; n = 25) clusters, as previously reported in the super-enhancer landscape. The expression patterns
APA, Harvard, Vancouver, ISO, and other styles
8

Mojard Kalkhoran, Somayeh, Sarah Heather Jane Chow, Jagdeep Singh Walia, et al. "VNUT and VMAT2 segregate within sympathetic varicosities and localize near preferred Cav2 isoforms in the rat tail artery." American Journal of Physiology-Heart and Circulatory Physiology 316, no. 1 (2019): H89—H105. http://dx.doi.org/10.1152/ajpheart.00560.2018.

Full text
Abstract:
ATP and norepinephrine (NE) are coreleased from peripheral sympathetic nerve terminals. Whether they are stored in the same vesicles has been debated for decades. Preferential dependence of NE or ATP release on Ca2+ influx through specific voltage-gated Ca2+ channel (Cav2) isoforms suggests that NE and ATP are stored in separate vesicle pools, but simultaneous imaging of NE and ATP containing vesicles within single varicosities has not been reported. We conducted an immunohistochemical study of vesicular monoamine transporter 2 (VMAT2/SLC18A2) and vesicular nucleotide translocase (VNUT/SLC17A9
APA, Harvard, Vancouver, ISO, and other styles
9

Adam, Yoav, Robert H. Edwards, and Shimon Schuldiner. "Expression and function of the rat vesicular monoamine transporter 2." American Journal of Physiology-Cell Physiology 294, no. 4 (2008): C1004—C1011. http://dx.doi.org/10.1152/ajpcell.00348.2007.

Full text
Abstract:
The vesicular monoamine transporters (VMATs) are essential proteins, involved in the storage of monoamines in the central nervous system and in endocrine cells, in a process that involves exchange of 2H+with one substrate molecule. The VMATs interact with various native substrates and clinically relevant drugs and display the pharmacological profile of multidrug transporters. Vesicular transporters suffer from a lack of biochemical and structural data due to the difficulties in their expression. In this work we present the high-level expression of rat VMAT2 (rVMAT2) in a stable a human embryon
APA, Harvard, Vancouver, ISO, and other styles
10

Lin, Chih-Chun, and William G. Ondo. "Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia." Journal of the Neurological Sciences 389 (June 2018): 48–54. http://dx.doi.org/10.1016/j.jns.2018.02.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "VMAT2 Inhibitor"

1

Horton, David B. "DISCOVERY OF GZ-793A, A NOVEL VMAT2 INHIBITOR AND POTENTIAL PHARMACOTHERAPY FOR METHAMPHETAMINE ABUSE." UKnowledge, 2012. http://uknowledge.uky.edu/pharmacy_etds/4.

Full text
Abstract:
Methamphetamine abuse is a serious public health concern affecting millions of people worldwide, and there are currently no viable pharmacotherapies to treat methamphetamine abuse. Methamphetamine increases extracellular dopamine (DA) concentrations through an interaction with the DA transporter (DAT) and the vesicular monoamine transporter-2 (VMAT2), leading to reward and abuse. While numerous studies have focused on DAT as a target for the discovery of pharmacotherapies to treat psychostimulant abuse, these efforts have been met with limited success. Taking into account the fact that methamp
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "VMAT2 Inhibitor"

1

Harriott, Nicole D., John P. Williams, Evan B. Smith, Haig P. Bozigian, and Dimitri E. Grigoriadis. "VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)." In Progress in Medicinal Chemistry. Elsevier, 2018. http://dx.doi.org/10.1016/bs.pmch.2017.12.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pedroso, Vinicius Sousa Pietra, João Vinícius Salgado, and Antonio L. Teixeira. "Tardive Dyskinesia." In Movement Disorders in Psychiatry, edited by Antonio L. Teixeira, Erin Furr Stimming, and William G. Ondo. Oxford University PressNew York, 2022. http://dx.doi.org/10.1093/med/9780197574317.003.0005.

Full text
Abstract:
Abstract Tardive dyskinesia is a syndrome defined by the emergence of hyperkinetic involuntary movements after the exposure to dopamine receptor antagonists, mainly antipsychotics and antiemetics. It involves two main clinical presentations: orofaciolingual and limb-truncal dyskinesias. There are several nonmodifiable (e.g., age, sex) and modifiable (e.g., dose and duration of exposure) risk factors for tardive dyskinesia. In this context, long-term use of dopamine antagonists should be avoided whenever possible to prevent the development of this condition. Once tardive dyskinesia develops, if
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "VMAT2 Inhibitor"

1

Gamez, Josep, Matilde Calopa, Esteban Muñoz, et al. "F40 Proof-of-concept study testing SOM3355, a VMAT2 inhibitor for the treatment of chorea in huntington’s disease." In EHDN Abstracts 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/jnnp-2021-ehdn.83.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Scart, Catherine, Nuria Reig, Raul Insa, and Kevin McAllister. "J014 SOM3355 has an atypical profile of VMAT2 inhibition." In EHDN and Enroll-HD 2024 abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jnnp-2024-ehdn.335.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'VMAT2 Inhibitor' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography